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ABSTRACT
Objective:To compare the efficacy and safety of a 7-day course of treatment with oral grepafloxacin,
400 mg once daily, and oral doxycycline, 100 mg twice daily, in patients with chlamydial cervicitis.
Methods: Women aged 18 years or older attending 17 sexually transmitted disease clinics in the
United States who had clinical signs ofmucopurulent cervicitis or who had a recent positive culture
or nonculture test for Chlamydia trachomatis or who had contact with a male partner with a positive
culture for C. trachomatis were enrolled into this randomized, double-blind, active-controlled clinical
study. The diagnosis of chlamydial cervicitis was based on culture for C. trachomatis. Patients were
randomized to receive a 7-day course of treatment with either oral grepafloxacin, 400 mg once daily,
or oral doxycycline, 100 mg twice daily. Response to therapy was assessed 3-8 days and 21-28 days
after completion of treatment. The primary measure of efficacy was eradication of C. trachomatis at
the 21-28 day follow-up visit. Clinical success, defined as improvement or complete resolution of the
signs and symptoms of cervicitis, was a secondary measure of efficacy.
Results: Of the 451 female patients enrolled, 228 received grepafloxacin and 223 received doxy-
cyeline. In all, 154/451 (35%) patients were evaluable at the 21-28 day follow-up (81 who received
grepafloxaein and 73 who received doxyeyeline). Mierobiologic and clinical success rates demon-
strated the equivalence of the two treatments. The C. trachomatis eradication rates were 96.3%
(78/81) and 98.6% (72/73) for patients receiving grepafloxacin or doxycycline, respectively. The two
study drugs were also equivalent in resolving clinical signs and symptoms, with clinical success
rates of 88.9% (64/72) and 89.5% (51/57) for patients treated with grepafloxacin and doxycycline,
respectively. Both drugs were well tolerated, with 47% of patients receiving grepafloxacin and 46%
of patients receiving doxycycline experiencing drug-related adverse events, none of which was
serious.
Conclusions: Seven days of treatment with oral grepafloxacin, 400 mg once daily, was as effective
as 7 days of treatment with oral doxyeyeline, 100 mg twice daily, in patients with cervieitis caused
by C. trachomatis. Both agents were well tolerated and had comparable safety profiles. Grepafloxa-
ein’s once-daily dosing regimen may offer advantages in terms of patient compliance. Infect. Dis.
Obstet. Gyneeol. 6:109-115, 1998. (C) 1998 Wiley-Liss, Inc.
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hblamydia
trachomatis is the sexually-transmitted
acterial pathogen with the highest incidence
in the United States, causing an estimated 4 mil-
lion infections each year. Around 2.6 million in-
fections occur in women and 1.8 million in men;
250,000 of these infections occur in infants,z Up to
75% of women with uncomplicated chlamydial in-
fection are asymptomatic,
3 making the actual num-
ber of infected individuals difficult to determine.
In some infected women, yellow or green mucopus
is apparent in the endocervical canal. There may
also be areas of edematous and friable cervical ec-
topy that bleed when manipulated. Urethral infec-
tion may also occur and, though usually asymptom-
atic, can be associated with dysuria and urinary fre-
quency.
4
Infection with C. trachomatis causes considerable
morbidity, particularly in women and their off-
spring. Chlamydial infection may cause minimal
discomfort initially, allowing it to remain undetec-
ted. C. trachomatis first infects the cervix and may
spread canalicularly to the endometrium, causing
endometritis. Serious damage may occur when the
organism ascends to the fallopian tubes, where it
may manifest as acute salpingitis, an important
cause of female infertility,s Chlamydial infection
has also been linked to ectopic pregnancy. Mater-
nal carriage of C. trachomatis is associated with a
high incidence of illness in the offspring, including
pneumonia and inclusion conjunctivitis.6,7 Left un-
treated, infected infants may harbor C. trachomatis
for 1-3 years, particularly in the nasopharynx, geni-
tal tract, or rectum.8
Preferred agents for the treatment of chlamydial
infection are oral doxycycline, 100 mg twice daily,
for 7 days or a single 1-g dose of oral azithromycin.
Noncompliance with multiple-dose regimens may
be a particular problem in asymptomatic individu-
als, resulting in treatment failure and thus persis-
tent infection and reinfection of sexual partners.
Grepafloxacin (previously called OPC-17116) is
a new, orally administered fluoroquinolone with
excellent in vitro activity against pathogens com-
monly associated with sexually transmitted dis-
eases, including Neisseria gonorrhoeae, C. trachomatis
and Ureaplasma urealyticum,9-11 which suggests that
it may be an effective therapeutic option in sexu-
ally transmitted infections. Its activity in vitro
against C. trachomatis (MICgo 0.125 lag/mL) is
superior to that of ofloxacin (MICgo 2.0 lag/
mL), lz,3 as is its elimination half-life (12 hours vs.
4 hours) (data on file), enabling it to be given as a
single daily dose.
Serum and tissue concentrations attained with
grepafloxacin also support its use in the treatment
of genitourinary infection. Following oral adminis-
tration, grepafloxacin concentrations in female
genital tract tissues were higher than serum con-
centrations, with concentration ratios ranging from
2.1-5.2 for the endometrium, myometrium, cervix,
portio vaginalis, ovary, and oviduct, indicating a
high rate of penetration into these tissues. 14 Grepa-
floxaci also accumulates in human polymorpho-
nuclear leukocytes, suggesting that it may be use-
ful in the treatment of infections caused by intra-
cellular bacteria, is
The above microbiologic and pharmacologic
profile, including potent activity in vitro against C.
trachomatis, led to the initiation of this clinical
study comparing grepafloxacin with doxycycline in
women with chlamydial endocervical infections.
SUBJECTS AND METHODS
The patients studied were recruited at 17 public
clinics for sexually transmitted diseases in the
United States between November 1993 and Au-
gust 1995. Patients eligible for enrollment in this
randomized, double-blind, active-controlled inves-
tigation were nonpregnant women aged 18 years or
over, practicing active contraception, who had signs
of mucopurulent cervicitis based on mucopus
within the endocervical canal or an endocervical
Gram stain containing -< 10 leukocytes per oil im-
mersion field. Women were also enrolled if they
had a recent positive culture or nonculture test for
C. trachomatis for which they had not received treat-
ment or if they had had contact with a male partner
with a positive culture for C. trachomatis.
A medical history was taken at the pretreatment
visit, and patients underwent a baseline physical
examination and clinical laboratory tests. The first
dose of antibiotic was given at this visit; patients
were randomized to receive 7 days of treatment
with either oral grepafloxacin, 400 mg once daily, or
oral doxycycline, 100 mg twice daily. Patients were
evaluated at follow-up visits 3-8 days and 21-28
days following completion of treatment. Patients
were instructed to refrain from unprotected sexual
contact until the 21-28 day posttreatment visit.
The study was approved by the Institutional Re-
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view Board at each participating center, and writ-
ten informed consent was obtained from all partici-
pants before enrollment.
Exclusion Criteria
Exclusion criteria included: pregnancy or lactation;
women of childbearing potential not practicing ac-
ceptable contraception; a history of allergy to qui-
nolone or tetracycline antibiotics; hospitalization
for a non-study-related illness or procedure; treat-
ment with antibiotics within 2 weeks prior to study
entry; treatment with a concomitant antimicrobial
agent other than topical antibiotic or antifungal
agents; treatment with an investigational drug or
device within 4 weeks prior to study entry; chronic
treatment with warfarin, diflunisal, fluconazole, or
theophylline; antacids or sucralfate taken within 4
hours of dosing; or a complicating infection, chronic
disease or disorder that could interfere with study
results, including active seizure disorders, hepatic
or gastrointestinal disease, terminal illness or se-
vere immunocompromised status, evidence of
chronic, ascending, or disseminated genital infec-
tion, evidence of active herpes simplex virus infec-
tion, or a concurrent disease requiring immediate
antibiotic treatment.
Microbiologic Investigations
At the pretreatment visit, an endocervical Gram
stain was examined for leukocytes and intracellular
gram-negative diplococci and vaginal cultures for
cervical cultures for N. gonorrhoeae, C. trachomatis,
U. urealyticum, and Mycoplasrna horninis were exam-
ined with the use of the routine methods of each
participating laboratory. Patients with a positive
culture for N. gonorrhoeae were withdrawn and
treated with an appropriate antibiotic. At the 3-8
day posttreatment visit, endocervical Gram stain
and cervical cultures for N. gonorrhoeae and C. tra-
chomatis were repeated. Patients with a positive
culture for N. gonorrhoeae were withdrawn. Endo-
cervical Gram stain and culture for C. trachornatis,
U. urealyticum, and 3/1. hominis were also obtained at
the 21-28 day posttreatment visit.
Susceptibility testing against grepafloxacin and
doxycycline was performed on every third isolate of
C. trachomatis from each study center. McCoy cell
monolayers were incubated in triplicate with the
specimen and the appropriate concentration of an-
tibiotic and plates incubated for 72 hours at 30C in
2% COz. Cells were then fixed and stained with
fluorescent antibody. Positive cultures were de-
fined as those showing ->1 characteristic fluores-
cent chlamydial intracytoplasmic inclusion and
negative cultures as those having minimal or no
nonspecific staining and no fluorescent chlamydial
inclusions.
Microbiologic Response
The primary measure of study drug efficacy was
microbiologic response to therapy. The microbio-
logic response was based on the eradication of C.
trachomatis as judged by a comparison of pre- and
posttreatment cultures. A patient with negative
cultures for C. trachomatis at the 21-28 day follow-
up visit was considered to be a microbiologic suc-
cess or cure. A patient with a positive culture for C.
trachomatis at the 21-28 day posttreatment visit was
considered to be a microbiologic failure. No at-
tempt was made to differentiate relapse from rein-
fection.
Clinical Response
Clinical response was assessed based on the reso-
lution of pretreatment signs and symptoms of cer-
vicitis. Disease-related symptoms reported by the
patient were dysuria, abnormal vaginal discharge,
and abnormal bleeding, while signs assessed by the
investigator were mucus color, cervical edema, cer-
vical erythema, and friability of the cervix. Severity
was graded by the examiner as mild, moderate, or
severe. Clinical response at both follow-up visits
was classified as follows:
cure (resolution of all signs and symptoms)
improvement (resolution/decrease in severity of
some signs and symptoms)
asymptomatic (no clinical signs or symptoms at
pre- or posttreatment visits)
failure (worsening, no change, or presence of
new signs or symptoms)
indeterminate (evaluation not possible because
of missing data)
Participants classified as ’cure’ or ’improvement’
were considered to be clinical successes.
Patient Populations
Microbiologically and clinically evaluable patients
were defined as follows:
met the inclusion criteria
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had a culture for C. trachomatis taken 3-8 days
posttreatment and were assessed and had a cul-
ture taken 21-28 days posttreatment
took no other antibiotics between initial dosing
and follow-up
missed no more than day of dosing with study
drug
had C. trachomatis isolated from pretreatment
specimens
Assessment of Adverse Events
Physical examination of patients was performed,
and the patient’s body weight, vital signs, and any
abnormalities were recorded at the pretreatment
visit and at each of the follow-up visits. Clinical
laboratory tests were performed on blood and urine
samples collected at the pretreatment and 3-8 day
TABLE I. Demographic characteristics of study
patients
Grepafloxacin, Doxycycline,
400 mg 100 mg
Patient once daily twice daily
characteristic (n 228) (n 223) P value*
Age (years)








Black 151 (66.5%) 146 (65.5%) 0.22
Caucasian 47 (20.7%) 56 (25. I%)
Other 29 (I 2.8%) 21 (9.4%)
Smoking habits
Non-smoker 171 (75.3%) 178 (79.8%) 0.52
Ex-smoker 6 (2.6%) 5 (2.2%)
Smoker 50 (22.0%) 40 (I 7.9%)
Alcohol consumptionb’c
Yes 32 (I 4. I%) 30 (I 3.5%) 0.93
No 195 (85.9%) 193 (86.5%)
Caffeine consumption
b’c
Yes 160 (70.5%) 167 (74.9%) 0.23
No 67 (29.5%) 56 (25.1%)
Illicit drug useb’c
Yes 10 (4.4%) 15 (6.7%) 0.30
No 217 (95.6%) 207 (92.8%)
Unknown 0 1(0.4%)
*P values were calculated using a linear model with pooled center and
treatment as factors for age and weight and using Cochran-Mantel-
Haenszel general association statistic with pooled center as strata for
others.
aSD, standard deviation.
bn 227 in the grepafloxacin group.
eYes daily or weekly; no rarely or never.
TABLE 2. Reasons for patient exclusions from
microbiologic and clinical efficacy analysis at the
21-28 day follow-up visit
Reason for Grepafloxacin Doxycycline
exclusion (n 146) (n 151)
Antibiotic taken between dosing
and end of treatment 0 3
Exit evaluation window violation 46 41
General unwillingness/withdrew
consent 0 2
Unprotected sexual intercourse 9 4
Inclusion criteria not met 2
Lost to follow-up 21 27
No positive culture at
pretreatment 108 109
Less than six doses of study drug
taken 5 4
Test of cure window violation 4 7
Withdrawal: other reasons 7
Withdrawal: positive pretreatment
gonorrhea culture 7 5
aPatients may have more than one reason for exclusion.
posttreatment visits. The tests were repeated at
the 21-28 day posttreatment visit only if clinically
indicated.
RESULTS
Of the 451 patients randomized to the study, 228
patients received grepafloxacin and 223 received
doxycycline. Table presents the demographic
characteristics for the patient population; the two
treatment groups were comparable for the demo-
graphic characteristics evaluated.
A total of 112 patients (49%) receiving grepa-
floxaci and 104 (47%) receiving doxycycline had
pretreatment endocervical cultures positive for C.
trachomatis. In addition, U. urea/yticum and 3/. homi-
his were isolated from 147 (64%) and 98 (43%) pa-
tients receiving grepafloxacin and 142 (64%) and 92
(41%) patients receiving doxycycline, respectively.
Microbiologic Response
Of the 451 patients randomized to the study, 154
patients were evaluable at the 21-28 day posttreat-
ment visit. The reasons for exclusion of the re-
maining 297 participants are listed in Table 2.
Table 3 presents chlamydial eradication rates at the
21-28 day posttreatment visit. C. trachomatis was
eradicated in 96.3% of patients (78/81) receiving
grepafloxacin and 98.6% (72/73) receiving doxycy-
cline. The 95% confidence interval for the differ-
ence between the two treatments confirmed the
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TABLE 3. Microbiologic response of Chlamydia trachomatis to grepafloxacin and doxycycline at the 21-28 day
posttreatment visit
Grepafloxacin, Doxycycline,
400 mg once daily 100 mg twice daily
(n 81) (n 73)
Assessment n % n % 95% CI
Eradication 78 96.3 72 98.6 -9.9%, 4.9%
Failure 3 3.7 1.4
a95% confidence interval is around the difference of microbiologic success rate (%); treatment comparison was the response rate of grepafloxacin minus
the response rate of doxycycline.
TABLE 4. Clinical response rates at the 21-28 day posttreatment visit
Grepafloxacin,
400 mg once daily
(n =81)
Doxycycline,
100 mg twice daily
(n 73)
n % n % 95% CI
b
Success 64 88.9 51 89.5
cure 54 75.0 45 78.9
improvement 10 13.9 6 10.5
Failure 8 I. 6 10.5
Asymptomatic 9 16
-11.2%, 11.7%
aThe denominator equals the total number of patients in the categories of success and failure.
bConfidence interval calculated based on a center-weighted method.
CData missing due to withdrawal for lack of response were mapped to ’failure.’
equivalence of the two study drugs in eradicating
this pathogen (95% CI -9.9%, 4.9%, P 0.622).
The MICs of grepafloxacin and doxycycline for 51
pretreatment C. trachomatis isolates were all -<0.25
pg/mL.
Clinical Response
Clinical response rates at the 21-28 day posttreat-
ment visit are shown in Table 4. Considering the
clinical success rate (cure plus improvement) at this
visit, 64/72 patients (88.9%) receiving grepafloxacin
and 51/57 (89.5%) receiving doxycycline were clini-
cal successes. The 95% confidence interval for the
difference between the two groups confirmed the
equivalence of grepafloxacin and doxycycline (95%
CI -11.2%, 11.7%).
Treatment-Related Adverse Events
A total of 172 drug-related, treatment-associated
adverse events was reported by 107 patients (47%)
in the grepafloxacin group, and 167 such events
were reported by 102 patients (46%) receiving
doxycycline (Table 5). Those most commonly ex-
TABLE 5. Most frequently reported drug-related,
treatment-associated adverse events during the
study
Body system-adverse Grepafloxacin Doxycycline
experience (n 228) (n 223)
Body as a whole
abdominal pain 6 (2.6%) 5 (2.2%)
headache 4 (I.8%) 13 (5.8%)
infection (4.8%) 3 (I.3%)
Digestive
diarrhea 9 (3.9%) 4 (I .8%)
nausea 37 (16.2%) 34 (15.2%)
vomiting 5 (2.2%) 20 (9.0%)
Nervous
dizziness 8 (3.5%) 5 (2.2%)
Skin and appendages
pruritus 6 (2.6%) 7 (3. I%)
Special senses
taste perversion 35 (I 5.4%) (0.4%)
Urogenital
leukorrhea 4 (I.8%) 7 (3. I%)
vaginitis 15 (6.6%) 21 (9.4%)
At least one drug-related
adverse event 107 (46.9%) 102 (45.7%)
Drug-related possible, probable, or unknown relationship to study
drug.
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perienced in the grepafloxacin group were nausea
(16%), taste perversion (15%), and vaginitis (6%),
and in the doxycycline group the most common
drug-related events were nausea (15%), vaginitis
(9%), and vomiting (9%). The incidences of head-
ache and vomiting were statistically significantly
higher in the doxycycline group: headachem
grepafloxacin 1.8%, doxycycline 5.8%, P 0.026;
vomitingmgrepafloxacin 2.2%, doxycycline 9.0%,
P 0.002. The incidence of taste perversion was
statistically significantly higher in the grepafloxacin
group (15.4% vs. 0.4%, P < 0.001). No serious treat-
mentassociated adverse events were reported, and
there were no deaths.
Three patients in each treatment group were
withdrawn because of adverse events. In five of
these patients the events were judged to be related
to study drug (grepafloxacin group: taste perver-
sion, nausea, mild rash, dyspepsia, dizziness; doxy-
cycline group: dyspepsia, abdominal pain, nausea/
vomiting, chest pain, dyspnea).
Clinical and Laboratory Tests
There were no clinically significant trends or
changes in body weight, vital signs or clinical labo-
ratory data that were indicative of study drug tox-
icity. Small changes in hematologic parameters,
within the normal range for both treatment groups,
were seen at both follow-up visits. Only isolated
cases of clinically significant serum chemistry ab-
normalities were detected.
DISCUSSION
Because of the insidious nature of chlamydial in-
fection and its potentially serious sequelae in in-
fected women and their infants, prompt and effec-
tive antimicrobial therapy is imperative. In addi-
tion to treating women with symptoms, however,
we must also improve patient identification to rec-
ognize the far greater number of asymptomatic in-
dividuals who also require antimicrobial therapy.
Strategies that may be employed include routine
testing of high-risk women, testing as part of infer-
tility investigations, and screening in women using
oral contraceptives prior to abortion and following
miscarriage and premature birth.6 In order to avoid
the serious sequelae of C. trachomatis, compliance
with treatment is essential; evidence suggests that
compliance is likely to be better with once-daily
than with twice-daily regimens.
16 Compliance
within clinical practice is likely to be less than that
observed during a clinical trial.
The primary aim of this study was to compare
the microbiologic and clinical efficacies of a 7-day
treatment with once-daily grepafloxacin and twice-
daily doxycycline in women with C. trachomatis en-
docervical infections. The overall microbiologic
and clinical success rates for the two study drugs
were statistically equivalent. C. trachomatis was
eradicated in more than 96% of cases in both treat-
ment groups at both posttreatment visits. Both
treatment regimens were well tolerated, and no
unique or unexpected laboratory findings were
seen.
In summary, a 7-day, once-daily treatment with
grepafloxacin was as effective as a 7-day, twice-
daily treatment with doxycycline. Grepafloxacin’s
activity against N. gonorrhoeae may expand its util-
ity to patients with gonorrhea, for whom antimicro-
bial treatment for chlamydial infection is also rec-
ommended because of the high incidence of coin-
fection. It may, therefore, provide a useful
alternative for the treatment of sexually transmit-
ted endocervical infections.
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